Bli medlem
Bli medlem

Du är här

2014-03-20

AstraZeneca: AstraZeneca proposes appointment of Ann Cairns as non-executive director

AstraZeneca today announced that Ann Cairns will be proposed to
shareholders for election as a Non-Executive Director at the
Company's Annual General Meeting on 24 April 2014. On election, the
Board proposes appointing Ann to AstraZeneca's Audit Committee.

Leif Johansson, AstraZeneca Chairman, said: "I'm delighted to propose
Ann Cairns for election to the AstraZeneca Board. Ann will bring more
than twenty years' in-depth financial and international business
experience to the Board and we look forward to welcoming her."

All current Directors will be presenting themselves for re-election,
in accordance with AstraZeneca's normal practice, at the Company's
AGM. Subject to shareholder approval, Ann will join the Board with
effect from the end of the AGM on 24 April 2014.

There are no directorships to disclose under paragraph (1) and no
disclosure obligations arise under paragraphs (2) to (6) of LR 9.6.13
R of the UK Listing Authority's Listing Rules in respect of this
proposed appointment.

- ENDS -

NOTES TO EDITORS

Ann Cairns - biographical details

Ann Cairns is President, International Markets for MasterCard,
responsible for the management of all markets and customer-related
activities outside North America. She is credited with building
sustainable, strong growth rates for the company, leading the rollout
of innovation, and building new global partnerships with governments,
telecommunication companies and organisations such as the World Food
Programme.

Ann brings more than 20 years' experience working in senior management
positions across Europe and the US, running global retail and
investment banking operations.

Prior to joining MasterCard in August 2011, Ann was head of the
Financial Industry Group with Alvarez & Marsal in London, where she
led the European team managing Lehman Brothers Holdings International
through the Chapter 11 process. Prior to that Ann was CEO,
Transaction Banking at ABN AMRO, and spent 15 years in senior
operational positions at Citigroup.

At the start of her career, Ann spent time as an award-winning
research engineer, culminating as the head of Offshore Engineer -
Planning for British Gas. Managing a team of more than 50 engineers,
Ann was the first woman qualified to work offshore in Britain.

Ann received a first class BSc in Pure Mathematics at Sheffield
University and an MSc with research into medical statistics from
Newcastle University.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of
cardiovascular, metabolic, respiratory, inflammation, autoimmune,
oncology, infection and neuroscience diseases. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:
www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)

Vanessa Rhodes +44 20 7604 8037 (UK/Global)

Ayesha Bharmal +44 20 7604 8034 (UK/Global)

Michele Meixell +1 302 885 2677 (US)

Jacob Lund +46 8 553 260 20 (Sweden)

Investor Enquiries

Karl Hård +44 20 7604 8123  mob: +44 7789 654364

Colleen Proctor + 1 302 886 1842 mob: +1 302 357 4882

Anthony Brown +44 20 7604 8067 mob: +44 7585 404943

Jens Lindberg +44 20 7604 8414 mob: +44 7557 319729

-----------------------------------------------------------
http://news.cision.com/se/astrazeneca/r/astrazeneca-proposes-appointment...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.